{"id":5909,"date":"2020-10-31T13:41:40","date_gmt":"2020-10-31T13:41:40","guid":{"rendered":"https:\/\/oncopeptides.com.haus.se\/about\/valberedning-2021\/"},"modified":"2026-03-06T10:13:18","modified_gmt":"2026-03-06T10:13:18","slug":"valberedning-2021","status":"publish","type":"about-us","link":"https:\/\/oncopeptides.com.haus.se\/sv\/om-oss\/corporate-governance\/kommitteer\/valberedning-2021\/","title":{"rendered":"Valberedning 2021"},"content":{"rendered":"<p><strong>Enligt principerna f\u00f6r utseende av valberedning i Oncopeptides AB (publ) ska valberedningen inf\u00f6r \u00e5rsst\u00e4mman 2021 best\u00e5 av ledam\u00f6ter utsedda av de tre st\u00f6rsta aktie\u00e4garna sett till r\u00f6stetal per den 30 september, samt styrelsens ordf\u00f6rande.<\/strong><\/p>\n<p>Valberedningens sammans\u00e4ttning har nu fastst\u00e4llts, och Oncopeptides meddelar idag att valberedningen inf\u00f6r \u00e5rsst\u00e4mman 2021 best\u00e5r av f\u00f6ljande personer som tillsammans representerar cirka 34 procent av antalet aktier och r\u00f6ster i bolaget baserat p\u00e5 den senast k\u00e4nda aktie\u00e4garinformationen i slutet av september.<\/p>\n<ul>\n<li>Staffan Lindstrand, utsedd av HealthCap VI L.P.<\/li>\n<li>Patrik Sobocki, utsedd av Stiftelsen Industrifonden<\/li>\n<li>Ulrik Gr\u00f6nvall, utsedd av Swedbank Robur Fonder<\/li>\n<li>Per Wold-Olsen, styrelsens ordf\u00f6rande<\/li>\n<\/ul>\n","protected":false},"featured_media":0,"parent":5990,"template":"","meta":{"_acf_changed":false},"protected-content":[],"class_list":["post-5909","about-us","type-about-us","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/about-us\/5909","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/about-us"}],"about":[{"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/types\/about-us"}],"version-history":[{"count":1,"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/about-us\/5909\/revisions"}],"predecessor-version":[{"id":5910,"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/about-us\/5909\/revisions\/5910"}],"up":[{"embeddable":true,"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/about-us\/5990"}],"wp:attachment":[{"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/media?parent=5909"}],"wp:term":[{"taxonomy":"protected-content","embeddable":true,"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/protected-content?post=5909"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}